BRAF/MEK 
Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events and Potential Drug Interactions.

@article{Czupryn2017BRAFMEKI,
  title={BRAF/MEK 
Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events and Potential Drug Interactions.},
  author={Maria P. Czupryn and Jennifer Cisneros},
  journal={Clinical journal of oncology nursing},
  year={2017},
  volume={21 4 Suppl},
  pages={11-29}
}
BACKGROUND BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E- and V600K-mutated unresectable or metastatic melanoma. However, these regimens are associated with adverse events (AEs) that may lead to unnecessary drug modifications and discontinuations or potentially serious sequelae. In addition, drug-drug interactions (DDIs) may result in AEs or altered therapeutic efficacy.
. OBJECTIVES This article presents consensus statements to guide nurses in the prevention, recognition, and… CONTINUE READING
1 Citations
36 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Zelboraf (vemurafenib) [Package insert

  • Genentech.
  • Retrieved from https://www.gene .com/download/pdf…
  • 2017
Highly Influential
4 Excerpts

Incidence and risk of xerosis with targeted anticancer therapies

  • S. J. Welsh, P. G. Corrie
  • Journal of the American Academy of Dermatology
  • 2015
Highly Influential
5 Excerpts

Cotellic (cobimetinib) [Package insert

  • Genentech.
  • Retrieved from https://www.gene .com/download/pdf…
  • 2016
Highly Influential
3 Excerpts

Eliquis ® ( apixaban ) [ Package insert ]

  • J. Bryce, C. B. Boers-Doets
  • 2017

List of cleared or approved companion diagnostic devices ( in vitro and imaging tools )

  • J. Valentine, V. R. Belum, +4 authors M. E. Lacouture
  • 2017

Similar Papers

Loading similar papers…